Department of Radiation Oncology, Ordensklinikum Linz Barmherzige Schwestern, Linz, Austria; Medical Faculty, Johannes Kepler University Linz, Linz, Austria
Auto-generated profile, based on publicly available information
Lukas Kocik
Department of Radiation Oncology, Ordensklinikum Linz Barmherzige Schwestern, Linz, Austria; Medical Faculty, Johannes Kepler University Linz, Linz, Austria
Background: Cancer patients are highly prone to infectious diseases. While undergoing antineoplastic treatment, the risk of severe symptoms upon infection increases, necessitating efficient protective measures, such as vaccination. For patients receiving radiotherapy, there is no specific information about humoral immunity. During the COVID-19 pandemic, serial antibody measurements were therefore offered to cancer patients, following SARS-CoV-2 vaccination while obtaining radiotherapy. Methods: Out of 74 enrolled patients, 46 met the inclusion criteria. Two cohorts were allocated, depending on an association with chemotherapy or pure radiotherapy. An additional healthy control cohort of 16 healthcare workers was enrolled. All participants followed a two-fold BNT162b2 vaccine schedule. SARS-CoV-2 binding antibodies were measured serially in a 7-day cycle for 35 days and over the long-term, using the Elecsys® Anti-SARS-CoV-2 immunoassay. Results: Cancer patients under pure radiotherapy have a comparable humoral vaccination response and long-term persistency of antibodies to healthy controls. Patients receiving additional chemotherapy show a significantly delayed immune response and decreased antibody titers. The vaccine was well tolerated in all cohorts. Conclusions: Pure radiotherapy in cancer patients does not interfere with the vaccine-induced humoral immune response or other immunogenetic aspects, whereas previous or simultaneous chemotherapy does. Findings are of particular relevance for future epidemic or pandemic scenarios.
Advances in radiotherapy (RT) techniques have facilitated the increasing use of hypofractionated treatment schedules, which may be particularly advantageous for elderly patients by reducing treatment burden while maintaining acceptable toxicity. This study aimed to evaluate survival and symptom palliation and to investigate whether different fractionation approaches affected toxicity and clinical outcomes in nonagenarian patients. This single-center retrospective cohort included 199 nonagenarians treated with RT between 2005 and 2023. Fractionation was classified as normofractionated (NF-RT), hypofractionated (HF-RT: >2Gy) and ultra-hypofractionated (UHF-RT: ≥5Gy). Outcomes were symptom control, acute ≥ Grade 2 (G2) toxicity, and overall survival (OS). Median age at RT was 92 years (range 90-101); 42% received curative and 58% palliative RT. Median OS of all patients was 11 months (palliative treatment: 7 months), with 1- and 5-year OS rates of 47% and 11% respectively. Overall, symptom improvement was documented in 73% of patients, with particularly high frequencies of improvement in tumor-related bleeding (95%) and ulceration (80%), pain improved in 65%. Acute ≥ G2 toxicity occurred in 21% (G3, 5%). Generally, UHF-RT and HF-RT had lower odds of ≥ G2 toxicity than NF-RT, however they were treated with lower doses (EQD2) to smaller target volumes. After adjustment for confounding factors, the hazards for all-cause death were only slightly higher for HF-RT and UHF-RT compared to NF-RT. Oligometastatic patients had almost identical survival as those without metastases, patients with breast cancer had a better survival than those with other entities. RT in selected nonagenarians achieved high frequencies of palliation with low severe toxicity. Hypofractionation was well tolerated without clear impact on survival.